A Genome-wide analysis of the response to inhaled beta2-agonists in Chronic Obstructive Pulmonary Disease

Short-acting β(2)-agonist bronchodilators are the most common medications used in treating chronic obstructive pulmonary disease (COPD). Genetic variants determining bronchodilator responsiveness (BDR) in COPD have not been identified. We performed a genome-wide association study (GWAS) of BDR in 57...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardin, Megan, Cho, Michael H., McDonald, Merry-Lynn, Wan, Emily, Lomas, David A., Coxson, Harvey O., MacNee, William, Vestbo, Jørgen, Yates, Julie C., Agusti, Alvar, Calverley, Peter MA, Celli, Bartolome, Crim, Courtney, Rennard, Stephen, Wouters, Emiel, Bakke, Per, Bhatt, Surya P, Kim, Victor, Ramsdell, Joe, Regan, Elizabeth A., Make, Barry J., Hokanson, John E., Crapo, James D., Beaty, Terri H., Hersh, Craig P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848212/
https://www.ncbi.nlm.nih.gov/pubmed/26503814
http://dx.doi.org/10.1038/tpj.2015.65

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848212/
https://www.ncbi.nlm.nih.gov/pubmed/26503814
http://dx.doi.org/10.1038/tpj.2015.65

Ejemplares similares